| Symbol | AVXL |
|---|---|
| Name | ANAVEX LIFE SCIENCES CORP. |
| Sector | HEALTH CARE |
| Region | North America |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) |
| Address | 51 WEST 52ND STREET,7TH FLOOR, NEW YORK, New York, 10019, United States |
| Telephone | +1 844 689-3939 |
| Fax | — |
| — | |
| Website | https://www.anavex.com |
| Incorporation | UNDEFINED |
| Incorporated On | — |
| Employees | — |
| Fiscal Year | — |
| Public Since | — |
| Exchanges | NASDAQ |
| Auditor | — |
| Audit Status | NOT PROVIDED |
| Reporting Status | — |
| CIK | — |
| Description | Anavex Life Sciences Corp is a clinical-stage biopharmaceutical company engaged in the development of differentiated therapeutics by applying precision medicine to central nervous system diseases with high unmet need. It analyzes genomic data from clinical studies to identify biomarkers, which are used to select patients that will receive the therapeutic benefit for the treatment of neurodegenerative and neurodevelopmental diseases. Its lead compound ANAVEX 2-73 is being developed to treat Alzheimers disease, Parkinsons disease, and potentially other central nervous system diseases, including rare diseases, such as Rett syndrome, a rare severe neurological monogenic disorder caused by mutations in the X-linked gene, methyl-CpG-binding protein 2. Additional info from NASDAQ: |
Anavex Life Sciences Highlights New Scientific Findings on Shared Biology Between Autism and Alzheimer’s Disease
Read moreAnavex Life Sciences Highlights New Scientific Findings on Shared Biology Between Autism and Alzheimer’s Disease
Read moreAnavex Life Sciences to Present at the 25th Annual Needham Virtual Healthcare Conference
Read moreAnavex Life Sciences to Present at the 25th Annual Needham Virtual Healthcare Conference
Read moreINVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Anavex Life Sciences Corp. - AVXL
Read moreNew Form SCHEDULE 13G/A - ANAVEX LIFE SCIENCES CORP. <b>Filed:</b> 2026-03-26 <b>AccNo:</b> 0000102909-26-000679 <b>Size:</b> 7 KB
Read more(80% Positive) ANAVEX LIFE SCIENCES CORP. (AVXL) Provides Update on treatments for adults
Read moreAnavex Life Sciences Provides Update on Regulatory Review in the EU for Blarcamesine to Treat Early Alzheimer’s Disease
Read more| Trial ID | Title | Phase | Indication | Status | Start Date | Completion Date | Source |
|---|---|---|---|---|---|---|---|
| NCT04314934 | OLE of Phase 2b/3 Study ANAVEX2-73-AD-004 | Phase2 | Alzheimer Disease | Completed | 2019-10-10 | 2024-06-14 | ClinicalTrials.gov |
| NCT03941444 | ANAVEX2-73 Study in Patients With Rett Syndrome | Phase3 | Rett Syndrome | Completed | 2019-05-06 | 2021-09-30 | ClinicalTrials.gov |
| Product Name | Type | Development Stage | Therapeutic Area | Study Status | Trial ID |
|---|---|---|---|---|---|
| Placebo oral capsules | DRUG | Phase PHASE2 | Schizophrenia | ACTIVE_NOT_RECRUITING | NCT06245213 |
| ANAVEX3-71 oral capsules | DRUG | Phase PHASE2 | Schizophrenia | ACTIVE_NOT_RECRUITING | NCT06245213 |
| ANAVEX3-71 | DRUG | Phase PHASE1 | Healthy | COMPLETED | NCT04442945 |
| Placebo oral liquid | DRUG | Phase PHASE2 | Rett Syndrome | COMPLETED | NCT04304482 |
| ANAVEX2-73 oral liquid | DRUG | Phase PHASE2 | Rett Syndrome | COMPLETED | NCT04304482 |
| Placebo oral capsule | DRUG | Phase PHASE2 | Alzheimer Disease | COMPLETED | NCT03790709 |
| Mid dose ANAVEX2-73 | DRUG | Phase PHASE2 | Alzheimer Disease | COMPLETED | NCT03790709 |
| High dose ANAVEX2-73 | DRUG | Phase PHASE2 | Alzheimer Disease | COMPLETED | NCT03790709 |
| Placebo | DRUG | Phase PHASE1 | Healthy | COMPLETED | NCT04442945 |
| ANAVEX2-73 | DRUG | Phase PHASE2 | Parkinson Disease Dementia | COMPLETED | NCT04575259 |
| ANAVEX2-73 Intravenous | DRUG | Phase PHASE2 | Alzheimer's Disease | COMPLETED | NCT02244541 |
| ANAVEX2-73 Oral | DRUG | Phase PHASE2 | Alzheimer's Disease | COMPLETED | NCT02244541 |